SANUWAVE Health Inc.'s Earnings Call Transcript for the Second Quarter of 2025
Sanuwave Health, Inc. (SNWV) announced strong Q2 2025 earnings, marking a significant milestone with record quarterly revenue of $10.2 million - a 42% increase from $7.2 million in Q2 2024.
The company's gross margin improved to 78.3%, up from 73.2% in the previous year. Sanuwave sold 116 UltraMist® systems in Q2 2025, a notable increase from the 72 systems sold in the year-ago quarter. The revenue from UltraMist® consumables also saw a 37% rise to $6.4 million. Operating income was $1.9 million, and net income reached $1.1 million. Adjusted EBITDA more than doubled to $3.4 million from $1.5 million in Q2 2024.
During the Q2 2025 Earnings Conference Call held on August 8, 2025, at 8:30 AM ET, Morgan C. Frank, Chairman and CEO of Sanuwave, along with Peter Sorensen, CFO and Secretary, provided insights into the company's performance. Other participants included Albert Hanser, Kyle Royal Bauser from ROTH Capital Partners, LLC, Research Division, and Christopher Michael Plahm from Tall Pines Capital, LLC.
Looking ahead, Sanuwave has provided guidance for Q3 2025 revenue to be between $12 million and $12.7 million, maintaining full-year 2025 revenue guidance of $48-$50 million, representing a 47-53% increase compared to 2024.
The results underscore significant revenue growth, strong sales of UltraMist systems, high gross margins, and improved profitability. However, the company reported some equity compensation costs that affected GAAP operating income comparably year-over-year. Sanuwave continues to focus on its patented non-invasive regenerative medicine technologies for wound care and other medical applications.
Transcripts of the earnings call are available online, along with an updated presentation made available on Sanuwave's website in the Investors section. Relevant analysis and news about Sanuwave can be found online as well. It is important to note that the conference call included forward-looking statements, which are not guarantees of future performance and involve risks and uncertainties. The company does not undertake to update any forward-looking statements, and actual results may differ materially from those projected in the forward-looking statements.
[1] Sanuwave Health, Inc. Form 10-Q for Q2 2025 was filed with the SEC the night before the conference call. [2] The earnings release for Q2 2025 was issued on the day of the conference call. [3] A description of these risks and uncertainties is included in Sanuwave's SEC filings. [4] The company does not undertake to update any forward-looking statements. [5] Actual results may differ materially from those projected in the forward-looking statements.
Investors should take note of Sanuwave Health, Inc.'s (SNWV) focusing on its patented non-invasive regenerative medicine technologies for future growth and profitability, as evidenced by the significant revenue growth, strong sales of UltraMist systems, high gross margins, and improved profitability. Importantly, potential investors should be aware of the risks and uncertainties involved in the projected future performance.
